Zhitong Finance App News, Yiming Onko-B (01541.HK) announced that the Group has submitted an application for IMM2510 to the Drug Evaluation Center of the People's Republic of China for phase III clinical trials to treat immunotherapy (IO) resistant non-small cell lung cancer (NSCLC), and recently submitted two phase III registered clinical trials for different types of lung cancer.

Zhitongcaijing · 10/02/2025 00:49
Zhitong Finance App News, Yiming Onko-B (01541.HK) announced that the Group has submitted an application for IMM2510 to the Drug Evaluation Center of the People's Republic of China for phase III clinical trials to treat immunotherapy (IO) resistant non-small cell lung cancer (NSCLC), and recently submitted two phase III registered clinical trials for different types of lung cancer.